BAYER IS NO STRANGER TO MAKING HEALTH CLAIMS (AD CIRCA 1899).
Recently, the FDA revised its position on the use of Aspirin as a preventative protocol in response to Bayer US wanting to change their Aspirin label to say that “it can help prevent heart attacks in healthy individuals”. An article by Dr. Mercola does a good job of summarizing the health risks and research studies on Aspirin. It shows that there were no preventative benefits of daily aspirin use, and in fact the side effects and risks are far greater than originally thought. While it doesn’t appear that Health Canada has made the same determination (at least not yet) the influence of the FDA on the worldwide community is powerful.
Read Dr. Mercola’s article here: http://tinyurl.com/ofdm8ae
Other pharmaceutical blood thinners, such as Warfarin and Pradaxa, each have long lists of side effects and health risks, yet are still on the market in Canada and widely used. Sadly, one of those health risks is death, as told in this CTV news story in April 2014, where Pradaxa had be linked to 281 deaths in Canada alone.
Read more here: http://nhppa.org/?p=8802
One very promising natural health product used to thin blood and prevent dangerous blood clots, Nattokinase, has been used for about 1,000 years without negative side effects or having caused a single death. Research on this enzyme has shown successful results for patients with cardiovascular health issues and benefits for some other chronic health issues as well. This newsletter discusses a variety of clinical uses and research on Nattokinase.
Read the newsletter here: http://tinyurl.com/nzonmby
Unfortunately Health Canada does not believe there is enough evidence to support the safe use of Nattokinase for patients in Canada and has banned it making the sale of it illegal in Canada. On Health Canada’s website page “Notice to Stakeholders of Nattokinase” they state that, “Blood thinners are used for the prevention of primary and secondary heart attacks and strokes. Since blood thinners carry the risk of internal bleeding, the health benefits from blood thinners must outweigh the risk of internal bleeding. Understanding the benefits versus the risks requires that there be sufficient supporting evidence.” If this same statement (and resulting removal of product) were applied to pharmaceutical blood thinners, would they still be on the market? If there were safer and effective alternatives available, wouldn’t you be interested having access to them?
